Terrorism discourse on French international broadcasting: <i>France 24</i> and the case of <i>Charlie Hebdo</i> attacks in Paris

This article offers an inquiry into the discursive construction of ‘terrorism’ by France 24, the French international broadcaster, in the aftermath of the attacks on Charlie Hebdo satirical magazine in January 2015. The article argues that the broadcaster seems to employ a relatively narrow definition of terrorism linking it to Islam and Muslims. France 24 portrays the attacks as an external phenomenon coming to France from outside. The blame is assigned to non-French factors, mainly to foreign extremist organisations, Islamist ideologues and overseas training. No reasons for violence are sought inside the country. Internal developments, such as discrimination, youth marginalisation, lack of educational and work opportunities, relations between law enforcement and the Muslim community that could potentially contribute to the acts, are not explored by the broadcaster’s investigative journalism. This narrow interpretation of ‘terrorism’ that assigns responsibility to Muslims, Islamic indoctrination and overseas training may further alienate Muslim communities in France’s already divided society. It points to narrow policy responses that focus mainly on stricter monitoring of Muslim minorities, on limiting combat and cross-border movement. This type of discourse excludes long-term policy solutions that address broader socio-politico-economic conditions in which ‘terrorism’ might flourish

The Rational Use of Complement Inhibitors in Kidney Diseases.

The development of complement inhibitors represented one of the major breakthroughs in clinical nephrology in the last decade. Complement inhibition has dramatically transformed the outcome of one of the most severe kidney diseases, the atypical hemolytic uremic syndrome (aHUS), a prototypic complement-mediated disorder. The availability of complement inhibitors has also opened new promising perspectives for the management of several other kidney diseases in which complement activation is involved to a variable extent. With the rapidly growing number of complement inhibitors tested in a rapidly increasing number of indications, a rational use of this innovative and expensive new therapeutic class has become crucial. The present review aims to summarize what we know, and what we still ignore, regarding complement activation and therapeutic inhibition in kidney diseases. It also provides some clues and elements of thoughts for a rational approach of complement modulation in kidney diseases